IJCRR - 5(6), March, 2013
TUBERCULOSIS DIAGNOSIS AND TREATMENT: NEGOTIATING THE SOLUTION AND IMPLEMENTATIONS
Author: Navjot Kaur, S.S. Bhatia
Tuberculosis (TB) is a pulmonary disease caused by Mycobacterium tuberculosis. Various factors are associated with the transmission of TB including the infectiousness of the patient, duration of exposure and the nature of the environment, where exposure occurs. Tuberculosis diagnosis is the key concern of contemporary health research worldwide. TB control has been achieved in high-income countries but remained a threat for middle and low income countries. Transmission of TB can be reduced by fast diagnosis and complete treatment. Appropriate information of control policies and their adequate implementations are mandatory to achieve the desired results. Lack of awareness, inadequate treatment and fall in appropriate implementation on TB control and prevention programs are prevalent factors which become the barrier to achieve the TB elimination target.
Keywords: Tuberculosis, Diagnosis, Treatment regime.
Navjot Kaur, S.S. Bhatia. TUBERCULOSIS DIAGNOSIS AND TREATMENT: NEGOTIATING THE SOLUTION AND IMPLEMENTATIONS International Journal of Current Research and Review. 5(6), March, 69-75
1. World Health Organization. Global Tuberculosis Report 2012. http://who.int/tb/publications/global report/gtbr12 main.pdf
2. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide. MMWR Morb Mortal Wkly Rep 2006; 55: 301-305.
3. Koch R. Die Aetiologie der Tuberculose: Berliner Klinische Wochenschrift 1882;19:22130. Pinner B, Pinner M, translators. Am Rev Tuberc. 1932; 25:298323.
4. The World Bank. Country and Lending Groups. http://data.worldbank.org/about/countryclassifications/country-and-lending-groups
5. World Health Organization. Global tuberculosis control: a short update to the 2009 report. http://whqlibdoc.who.int/publications/2009/9 789241598866 eng.pdf
6. Fox W. Realistic chemotherapeutic policies for tuberculosis in the developing countries. BMJ. 1964;1:13542.
7. Fendall NR. Auxiliaries and primary medical care. Bull N Y Acad Med. 1972;48:1291300.
8. Fox W. Pillip Ellman Lecture: The modern management and therapy of pulmonary tuberculosis. Proc R Soc Med. 1977; 70:415.
9. Mount FW, Ferebee SH. United States Public Health Service Cooperative investigation of antimicrobial therapy of tuberculosis. V: report on thirty-two week observations on combinations of isoniazid, streptomycin, and para-amino salicylic acid. Am Rev Tuberc. 1954;70:5216.
10. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. Geneva: World Health Organization, 2003. 11. Rouillon A. The mutual assistance programme of the IUATLD. Development, contribution, and significance. Bull Int Union Tuberc Lung Dis. 1991;66:15972.
12. Raviglione MC, Uplekar M. WHOs new Stop TB strategy. Lancet. 2006; 367:9525.
13.  Coggin WL, Ryan CA, Holmes CB. Role of the US Presidents emergency plan for AIDS relief in responding to tuberculosis and HIV coinfection. Clin Infect Dis. 2010;50 (Suppl 3):S2559.
14. Laxminarayan R, Klein EY, Adeyi O. Global investments in TB control: economic benefits. Health A (Millwood). 2009; 28:w73042.
15. World Health Organization. The global plan to stop TB 20112015: transforming The fight Towards The elimination of tuberculosis http://www.stoptb.org/assets/documents/gl obal/plan/TB GlobalPlanToStopTB2011- 2015.pdf
16. Shah N, Wright A, Bai G, Barrera L, Boulahbal F, Martan-Casabona N, Worldwide emergence of extensively drugresistant tuberculosis. Emerg Infect Dis. 2007;13:3807.
17. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Report no. WHO/HTM/TB/2010.3. Geneva: The Organization; 2010
18. World Health Organization (2008). Countries with XDR-TB confirmed cases as of June 2008.
19. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide. MMWR Morb Mortal Wkly Rep 2006; 55: 301-305.
20. World Health Organization. Global Tuberculosis control 2010. http://whqlibdoc.who.int/publications/2010 /9789241564069 eng.pdf
21. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010; 181:806.
22. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368:157580.
23. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363:100515.
24. Cox HS, Sibilia K, Feuerriegel S, Kalon S, Polonsky J, Khamraev AK, Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med. 2008; 359:2398400.
25. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, Emer-gence of increased resistance and extensively drug-resistant tuberculosis despite treat-ment adherence, South Africa. Emerg Infect Dis. 2010;16:26471.
26. Lnnroth K, Castro KG, Chakayah JM, Chauhan LS, Floyd K, Glaziou P, Tuberculosis control and elimination 201050: cure, care, and social development. Lancet. 2010;375:181429.
27. Pantoja A, Floyd K, Unnikrishnan KP, Jitendra R, Padma MR, Lal SS, Economic evaluation of publicprivate mix for tuberculosis care and control, India. Part I. Socio-economic pro le and costs among tuberculosis patients. Int J Tuberc Lung Dis. 2009;13:698704.
28. World Health Organization. http://who.int/tb/laboratory/mtbrifrollout/en/.
29. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis. 2006; 6:71025.